Search
Now showing items 1-10 of 20
COVID-19 and substance use disorders: a review of international guidelines for frontline healthcare workers of addiction services
(2022-03)
People with substance use disorders may be at a greater risk of contracting COVID-19 infection and developing medical complications. Several institutional and governmental health agencies across the world developed ad hoc ...
Building trust in artificial intelligence and new technologies in mental health
(2022-04)
In 2019, the Topol review was published on behalf of the secretary of state for health and social care in the UK, preparing the healthcare workforce to deliver the digital future.1 A multidisciplinary team of experts, ...
Associations between mental and physical conditions in children and adolescents: An umbrella review
(2022-06)
We mapped the evidence on the type and strength of associations between a broad range of mental and physical conditions in children and adolescents, by carrying out an umbrella review, i.e., a quantitative synthesis of ...
Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model
(2022-02)
Donepezil, galantamine, rivastigmine and memantine are potentially effective interventions for cognitive impairment in dementia, but the use of these drugs has not been personalised to individual patients yet. We examined ...
Development and validation of a meta-learner for combining statistical and machine learning prediction models in individuals with depression
(2022-05)
The debate of whether machine learning models offer advantages over standard statistical methods when making predictions is ongoing. We discuss the use of a meta-learner model combining both approaches as an alternative. ...
A dose–effect network meta-analysis model with application in antidepressants using restricted cubic splines
(2022-02)
Network meta-analysis has been used to answer a range of clinical questions about the preferred intervention for a given condition. Although the effectiveness and safety of pharmacological agents depend on the dose ...
Dose–effect meta-analysis for psychopharmacological interventions using randomised data
(2022-01)
Objective The current practice in meta-analysis of the effects of psychopharmacological interventions ignors the administered dose or restricts the analysis in a dose range. This may introduce unnecessary uncertainty and ...
Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials
(2022-01)
Valid assessment of drug efficacy and safety requires an evidence base free of reporting bias. Using trial reports in Food and Drug Administration (FDA) drug approval packages as a gold standard, we previously found that ...
Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil
(2022-02)
The association between early improvement and subsequent change in cognition is unexamined in antidementia clinical trials. We aimed to examine the consequences of early-response to antidementia medication in Alzheimer's ...
Pharmacological and non-pharmacological interventions for adults with ADHD: protocol for a systematic review and network meta-analysis
(2022-02)
It is unclear how pharmacological and non-pharmacological interventions compare with each other in terms of efficacy and tolerability for core symptoms and additional problems in adults with attention-deficit/hyperactivity ...